The potential risks of opening the mind’s eye with psychedelic therapies
Koenig-Robert, Keogh and PearsonOctober 2025
Abstract
Psychedelic therapy is on the rise, as its legalisation is ongoing in multiple countries. Here, we write a note of warning regarding recent reports that people with aphantasia (a blind mind's eye) have acquired visual mental imagery after using psychedelics. While the prospect of gaining, or indeed increasing, visual mental imagery is appealing to many, strong mental imagery has been associated with a range of mental conditions. How 'switching on' visual imagery in people with aphantasia or increasing its strength in neurotypical individuals might impact mental health remains unknown. We advocate for increased awareness of this issue and its ethical implications, particularly regarding informed consent.
Our summary in plain words
What This Study Is About
How They Studied It
What They Found
What This Might Mean
One Interesting Detail
This summary was written with AI and may contain errors. Check the original paper.
Authors
Roger Koenig-Robert
School of Psychology, University of New South Wales
4 papers in the libraryRebecca Keogh
17 papers in the libraryJoel Pearson
35 papers in the library
Cite this paper
Koenig-Robert, R., Keogh, R., & Pearson, J. (2025). The potential risks of opening the mind’s eye with psychedelic therapies. Cortex, 191, 167–171. doi:10.1016/j.cortex.2025.08.002
Topics
Most-cited researchers
Recruit participants for your study
We can help you reach people across the imagery spectrum, from aphantasia to hyperphantasia.
Partner with usImage-Free Insights
A short note from our founder, Tom Ebeyer, every other week, plus occasional news and invitations to take part in studies. Change what you get from any email.